Approval Year
| Substance Class |
Concept
|
| Record UNII |
95E1ZQM329
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
95E1ZQM329
Created by
admin on Sat Dec 16 14:17:48 GMT 2023 , Edited by admin on Sat Dec 16 14:17:48 GMT 2023
|
PRIMARY | |||
|
C120068
Created by
admin on Sat Dec 16 14:17:48 GMT 2023 , Edited by admin on Sat Dec 16 14:17:48 GMT 2023
|
PRIMARY | NCIT |
This is a non-substance concept
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->LIGAND |
The proposed mechanism of action involves use of the monoclonal antibody component of the protein conjugate to target lung adenocarcinoma cells, thus delivering the urease to the tumor site. At the target site, the urease alters the pH in the local milieu, resulting in an alkalinization of the local tumor environment. In addition, the enzyme produces a high local concentration of ammonia. This combined activity leads to death of the tumor cells.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
This is a non-substance concept